Study: State Laws Shape Peptide Access in Sexual Medicine

Where you live may matter just as much as what your doctor prescribes. A 2026 study published in Sexual Medicine suggests that patients seeking peptide-based therapies for sexual health concerns face dramatically different levels of access depending on their state of residence — and that federal approval status alone does not explain those differences. The research, conducted by Quesada, Ahmed, Nakamura, and colleagues, offers one of the first systematic, state-by-state comparisons of the structural factors shaping whether patients can realistically obtain these emerging therapies.

What This Study Found

Researchers conducted a cross-sectional analysis of all 50 U.S. states and the District of Columbia, evaluating each jurisdiction through the lens of three proxy variables that reflect the practical feasibility of receiving peptide-based sexual medicine care:

• Telehealth prescribing permissiveness — how broadly state law allows clinicians to initiate and manage care remotely
• Nurse practitioner (NP) practice authority — whether NPs can practice and prescribe independently without physician oversight
• Availability of FDA-registered 503B outsourcing facilities — the presence of compounding pharmacies that meet federal manufacturing standards, normalized by state population

Each variable was coded on a standardized scale and combined into a composite Peptide Access Environment Score (PAES). States were then grouped into high-, moderate-, and low-access tiers based on their scores.

The findings revealed substantial interstate variability, with PAES values ranging from 0.33 to 1.56. High-access environments clustered predominantly in the Northeast and West, while low-access states were most frequently observed in the South and parts of the Midwest. Regional differences were statistically significant (p < .001), suggesting these disparities are unlikely to be due to chance.

Perhaps most notably, researchers identified a meaningful discordance between telehealth permissiveness and compounding infrastructure. Multiple states were found to allow telehealth initiation of care yet lacked in-state 503B compounding facilities — meaning a clinician could legally prescribe but patients might face significant barriers to actually obtaining the therapy. Conversely, some states had robust compounding capacity but maintained restrictive telehealth regulations, limiting which clinicians could initiate care and how. This mismatch, the study suggests, creates a patchwork access landscape that cannot be easily navigated by patients or providers without detailed local knowledge.

Clinical Significance

The study's authors argue that state-level healthcare delivery policies and infrastructure may meaningfully influence patient access to peptide-based sexual medicine therapies independent of peptide-specific regulatory status at the federal level. This is a critical distinction. Even when a compounded peptide therapy is legally available under federal guidelines, the structural environment of a given state — its telehealth rules, its NP scope of practice laws, its compounding pharmacy density — may effectively determine whether a patient can realistically access that therapy.

For clinicians, the research suggests that practicing in a high-PAES state may confer meaningful advantages in care delivery: greater flexibility in how patients are evaluated, broader prescriber workforce capacity, and more accessible compounding pharmacy infrastructure. In contrast, clinicians in low-PAES states may face structural barriers that limit their ability to offer the full spectrum of available options to their patients, regardless of clinical appropriateness.

The authors developed what they describe as a clinician-friendly framework for identifying geographic disparities — a practical tool intended to help providers understand the regulatory and logistical environment in which they are operating. This kind of structured, transparent methodology, grounded in publicly available data, may be particularly useful as the field of peptide-based sexual medicine continues to evolve rapidly.

Current Access and Compliance Context

Peptide-based therapies occupy a nuanced regulatory space in the United States. While some peptides have received FDA approval for specific indications, others are accessed through compounding pharmacies operating under Section 503B of the Federal Food, Drug, and Cosmetic Act. These FDA-registered outsourcing facilities are subject to current good manufacturing practice (cGMP) standards and oversight, but their geographic distribution is uneven — a reality that this study quantifies and maps in a systematic way for the first time.

State telehealth laws have also evolved considerably since the COVID-19 public health emergency, when many states relaxed restrictions on remote prescribing. As those emergency provisions have expired or been codified into permanent law in some states — while being rolled back in others — a new and complex interstate regulatory landscape has emerged. This study captures that variation as it existed at the time of data collection and provides a reproducible methodology that could be updated as laws continue to change.

It is important to note that the study does not evaluate whether any specific peptide therapy is safe or effective for sexual medicine indications. The authors focused exclusively on access infrastructure and delivery system characteristics, not clinical outcomes. Patients and providers should consult current FDA guidance and work only with licensed clinicians and compliant compounding facilities when considering these therapies.

What Patients Should Know

If you are a patient interested in learning about peptide-based options in sexual medicine, the research suggests that your geographic location may significantly shape what is practically available to you — even before your first conversation with a clinician. This does not mean that care is unavailable if you live in a lower-access state, but it does mean that navigating access may require additional steps, such as working with a telehealth provider licensed in a more permissive state, or identifying a 503B-compliant compounding pharmacy that can legally ship to your location.

The study also highlights that nurse practitioners, who often serve as primary care and specialty providers in underserved areas, may face additional restrictions in lower-access states that limit their ability to independently manage these therapies. Understanding who can prescribe in your state — and under what conditions — is an important part of the conversation to have with any prospective provider.

Patients are encouraged to ask prospective clinicians directly about their experience with peptide-based sexual medicine, their knowledge of state compounding regulations, and whether they are working with FDA-registered facilities. These are not unreasonable questions, and a well-informed provider should be able to answer them clearly.

As with any emerging area of medicine, the evidence base for specific peptide therapies continues to develop. Making informed decisions means partnering with a qualified clinician who stays current with both the science and the regulatory environment.

Conclusion

The research by Quesada, Ahmed, Nakamura, and colleagues represents an important step toward understanding why access to peptide-based sexual medicine therapies varies so widely across the United States. By moving beyond federal approval status and examining the structural determinants of access — telehealth law, NP authority, and compounding infrastructure — the study provides a more complete and actionable picture of the access landscape. The finding that these factors create statistically significant regional disparities underscores the need for patients and providers alike to understand the specific environment in which they are operating.

As this field continues to evolve, access to knowledgeable, compliant providers will be essential. The Peptide Association maintains a directory of qualified clinicians who are familiar with current regulatory and clinical standards. To find a provider near you, visit peptideassociation.org/find-a-doctor.

---

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The content summarizes published research and should not be used as a substitute for professional medical consultation. Always speak with a licensed healthcare provider before making decisions about any medical therapy. Regulatory and legal frameworks described in this article are subject to change.

---

Citation (AMA Style): Quesada SG, Ahmed Z, Nakamura HS, et al. Access without approval: state-level determinants of peptide availability in sexual medicine. Sex Med. 2026;14(4):qfag050. doi:10.1093/sexmed/qfag050. PMID: 42394939.